Cell & Gene: The Podcast

Cell & Gene: The Podcast

Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset

Jul 8, 2021 · 24m

✨ AI Summary

Rachelle Jacques on Enzyvant's lead asset RVT-802.
Update on FDA approval for congenital athymia.
Discusses tissue-based therapies and patient focus.

Guests on This Episode

RJ

Rachelle Jacques

1 podcast appearance

More from Cell & Gene: The Podcast

Advancing Cell Therapy Toward a Functional Cure for T1D With Forthcoming BetaNova's Jonathan Rigby and Will Rust, Ph.D.

Oct 8, 2026 · 24m

Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D.

Sep 24, 2026 · 27m

Shaping Drug Development by Starting with the Disease with Roche's Sylke Poehling, Ph.D.

Sep 10, 2026 · 18m

Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous

Aug 27, 2026 · 40m

View all episodes →